BR0010077A - Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas - Google Patents

Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas

Info

Publication number
BR0010077A
BR0010077A BR0010077-3A BR0010077A BR0010077A BR 0010077 A BR0010077 A BR 0010077A BR 0010077 A BR0010077 A BR 0010077A BR 0010077 A BR0010077 A BR 0010077A
Authority
BR
Brazil
Prior art keywords
protein
retroviral
gene
enzyme
integrase
Prior art date
Application number
BR0010077-3A
Other languages
English (en)
Inventor
Zeger Debyser
Erik De Clercq
Peter Cherepanov
Wim Pluymers
Original Assignee
K U Leuven Res & Dev Universit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K U Leuven Res & Dev Universit filed Critical K U Leuven Res & Dev Universit
Publication of BR0010077A publication Critical patent/BR0010077A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "GENE SINTéTICO PARA EXPRESSãO DE UMA PROTEìNA RETROVIRAL ATIVA EM EUCARIOTAS". A presente invenção se caracteriza por um gene sintético ou região de um gene o qual faz uso aprimorado de um códon comparado ao gene do tipo silvestre e o qual se destina à expressão em alto nível de uma proteína retroviral em células eucariotas, a proteína retroviral expressa tendo atividade enzimática na célula eucariota. Além disso, a invenção se caracteriza por um gene sintético ou região de um gene que codifica uma enzima retroviral ou parte de uma enzima retroviral normalmente expressa em uma célula de mamífero ou outra em que pelo menos um códon não preferido no gene do tipo silvestre que codifica a enzima tenha sido substituído por um códon preferido que codifica o mesmo aminoácido. A proteína retroviral pode ser uma protease, transcriptase reversa, proteína integrase ou um precursor da poliproteína gag-pol da mesma. Em uma concretização, a proteína retroviral com atividade enzimática é uma proteína lentiviral. Em outras concretizações, a proteína enzimaticamente ativa é uma enzima pol. Em concretizações mais preferidas, a proteína enzimaticamente ativa é uma integrase lentiviral. Em uma concretização ainda mais preferida, a enzima é uma enzima do HIV. Em concretizações mais preferidas, a proteína enzimaticamente ativa é integrase de HIV. A presente invenção também inclui um método de detecção para a integrase intracelular usando-se um gene repórter sem promotor.
BR0010077-3A 1999-04-26 2000-04-26 Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas BR0010077A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99201306 1999-04-26
EP00200171 2000-01-18
PCT/EP2000/003765 WO2000065076A2 (en) 1999-04-26 2000-04-26 Synthetic gene for expressing active retroviral protein in eukaryotes

Publications (1)

Publication Number Publication Date
BR0010077A true BR0010077A (pt) 2002-01-15

Family

ID=26071747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010077-3A BR0010077A (pt) 1999-04-26 2000-04-26 Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas

Country Status (11)

Country Link
EP (1) EP1183381A2 (pt)
JP (1) JP2002542791A (pt)
AU (1) AU778106B2 (pt)
BR (1) BR0010077A (pt)
CA (1) CA2369058A1 (pt)
HU (1) HUP0201019A2 (pt)
IL (1) IL146090A0 (pt)
NO (1) NO20015168L (pt)
PL (1) PL351988A1 (pt)
RU (1) RU2001131728A (pt)
WO (1) WO2000065076A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2395269C (en) * 1999-12-23 2015-12-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AUPQ580300A0 (en) * 2000-02-23 2000-03-16 National Cancer Centre Of Singapore Pte Ltd Genetic analysis
GB0009760D0 (en) * 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US6835568B2 (en) 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
DE602004030104D1 (de) * 2003-05-06 2010-12-30 Nat Inst Of Advanced Ind Scien System zur bestimmung der aktivität mehrerer gentranskriptionen
CA2623531C (en) * 2005-10-07 2013-12-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
JP6824594B2 (ja) 2014-09-11 2021-02-03 Jnc株式会社 合成遺伝子の設計方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468629A (en) * 1993-04-13 1995-11-21 Calhoun; Cornelia Method of promoting in vitro homologous recombination transfection in mammalian cells using the RecA protein
US5434065A (en) * 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
US5811270A (en) * 1994-05-20 1998-09-22 Grandgenett; Duane P. In vitro method for concerted integration of donor DNA molecules using retroviral integrase proteins
US6200811B1 (en) * 1996-04-02 2001-03-13 The Regents Of The University Of California Cell transformation vector comprising an HIV-2 packaging site nucleic acid and an HIV-1 GAG protein
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
EE9900343A (et) * 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
WO2000065076A2 (en) 2000-11-02
RU2001131728A (ru) 2004-02-20
AU4557900A (en) 2000-11-10
NO20015168D0 (no) 2001-10-23
JP2002542791A (ja) 2002-12-17
EP1183381A2 (en) 2002-03-06
CA2369058A1 (en) 2000-11-02
WO2000065076A3 (en) 2001-12-13
NO20015168L (no) 2001-12-14
HUP0201019A2 (en) 2002-08-28
PL351988A1 (en) 2003-07-14
AU778106B2 (en) 2004-11-18
IL146090A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
BR0010077A (pt) Gene sintético para expressão de uma proteìna retroviral ativa em eucariotas
Tokumitsu et al. Activation mechanisms for Ca2+/calmodulin-dependent protein kinase IV. Identification of a brain CaM-kinase IV kinase.
Roblin Metabolite antagonists.
Weisiger et al. Thiol S-methyltransferase from rat liver
Bellomo et al. Increase in cytosolic Ca2+ concentration during t-butyl hydroperoxide metabolism by isolated hepatocytes involves NADPH oxidation and mobilization of intracellular Ca2+ stores
Olken et al. Inactivation of macrophage nitric oxide synthase activity by NG-methyl-L-arginine
Arribas et al. Kinetic studies of the differential effect of detergents on the peptidase activities of the multicatalytic proteinase from rat liver.
TR199801419T2 (xx) S�lfone amino asit t�revleri ve ayn� i�erikte metaloproteinez �nleyicileri.
Yang The association between cytochrome P‐450 and NADPH‐cytochrome P‐450 reductase in microsomal membrane
DK466185D0 (da) Substituerede 3-aminopropanphosponsyrlingforbindelser samt deres fremstilling og anvendelse
BR0315595A (pt) Prato descartável tendo uma ergometria aperfeiçoada
Sondhi et al. Domain interactions in protein tyrosine kinase Csk
NO993709L (no) Stabilisert blanding omfattende fibrinogen
TR200101417T2 (tr) Sefuroksim aksetil içeren kompozisyonlar.
Li et al. Okadaic acid and microcystin-LR directly inhibit the methylation of protein phosphatase 2A by its specific methyltransferase
Ivanetich et al. Explanation of the non-hyperbolic kinetics of the glutathione S-transferases by the simplest steady-state random sequential Bi Bi mechanism
Rivlin et al. Regulation of hepatic FAD levels by thyroid hormone
Baum et al. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation
Anderson et al. Inhibition of mitochondrial and Paracoccus denitrificans NADH-ubiquinone reductase by oxacarbocyanine dyes: A structure-activity study
Christiansen et al. A study on the role of protein kinase C and intracellular calcium in the activation of superoxide generation
ARAI et al. Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase II. Inhibition by α-methylated substrate-analogue monoamines, α-methyltryptamine, α-methylbenzylamine and two enantiomers of α-methylbenzylamine
Rubinek et al. The catalytic properties of the reverse transcriptase of the lentivirus equine infectious anemia virus
Alonso et al. Effect of Tris (hydroxymethyl) aminomethane on isolated sarcoplasmic reticulum vesicles
Habecker et al. Developmental regulation of neurotransmitter phenotype through tetrahydrobiopterin
Edgar et al. Biosynthesis in Escherichia coli of sn-glycerol 3-phosphate, a precursor of phospholipid. Palmitoyl-CoA inhibition of the biosynthetic sn-glycerol-3-phosphate dehydrogenase.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]